Atara Biotherapeutics (ATRA) is scheduled to report Q1 earnings on May 14, 2026. Analysts estimate EPS of $0.85 and quarterly revenue of $2.17M.

In the most recent quarter (Q4), Atara Biotherapeutics reported EPS of $-0.25, missing estimates of $-0.07 by 2.57%. Revenue came in at $1.59M, missing the estimate of $1.63M by 0.02%.

Over the last 4 quarters, Atara Biotherapeutics has averaged an EPS surprise of 1.89% and a revenue surprise of 6.15%.